TGNA Stock Chart & Stats
€1.32
€0.08(12.28%)
At close: 4:00 PM EST
€1.32
€0.08(12.28%)
Day’s Range― - ―
52-Week Range€0.68 - €1.49
Previous CloseN/A
Volume0.00
Average Volume (3M)2.01K
Market Cap
€199.25M
Enterprise Value€103.55M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding278,559,940
10 Day Avg. Volume3,027
30 Day Avg. Volume2,006
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€8.15M
Bulls Say, Bears Say
Bulls Say
Immunotherapy R&D FocusTransgene's strategic focus on immunotherapies and therapeutic vaccines is a durable structural advantage: oncology immunotherapy demand is multi-year, and success in clinical programs or partner deals can create long-term value. The focus aligns R&D with high unmet medical need and sustained market interest.
Platform DifferentiationSpecialization in individualized and viral-vector approaches creates technical differentiation and higher barriers to entry. These platforms can enable tailored treatments and attractive licensing or partnership opportunities, supporting durable competitive positioning if clinical validation is achieved.
Low Leverage / Equity BaseA very low debt load and sizable equity base reduce near-term solvency risk and provide financial flexibility for a clinical-stage biotech. This structural balance sheet strength lengthens runway relative to highly levered peers and supports the ability to fund R&D or negotiate partnerships without immediate default risk.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate the business is cash-consuming and reliant on external financing. Over time this raises dilution and funding risk, can force program prioritization or delays, and constrains strategic optionality until sustainable cash generation or significant partner funding occurs.
Collapsing RevenueA near-total revenue collapse materially reduces internal funding capacity and reflects volatile partner or milestone income. Structural reliance on lumpy collaboration receipts means top-line unpredictability, weakening the company's ability to self-fund development and increasing dependency on external capital.
Sustained Net LossesDeep, ongoing operating losses and extremely negative margins signal that current operations are not self-sustaining. Over the medium term this pressures returns to shareholders, heightens fundraising frequency, and can erode negotiating leverage with partners unless clinical progress visibly reduces technical and regulatory risk.
Transgene News
TGNA FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.68 and its highest was €1.49 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €199.25M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 55 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in DE:TGNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―